Antonis C Antoniou

List of Publications by Year in Descending Order

199 papers	15,480 citations	62 h-index	122 g-index
213 ext. papers	19,789 ext. citations	10 avg, IF	5.43 L-index

#	Paper	IF	Citations
199	Cancer Risks Associated With and Pathogenic Variants.. *Journal of Clinical Oncology*, **2022**, JCO2102112	2.2	7
198	Oral Contraceptive Use in BRCA1 and BRCA2 Mutation Carriers: Absolute Cancer Risks and Benefits.. *Journal of the National Cancer Institute*, **2022**,	9.7	1
197	Predicting the Likelihood of Carrying a or Mutation in Asian Patients With Breast Cancer.. *Journal of Clinical Oncology*, **2022**, JCO2101647	2.2	1
196	The future of early cancer detection.. *Nature Medicine*, **2022**, 28, 666-677	50.5	7
195	Unselected Population Genetic Testing for Personalised Ovarian Cancer Risk Prediction: A Qualitative Study Using Semi-Structured Interviews. *Diagnostics*, **2022**, 12, 1028	3.8	1
194	Overlap of high-risk individuals predicted by family history, and genetic and non-genetic breast cancer risk prediction models: implications for risk stratification.. *BMC Medicine*, **2022**, 20, 150	11.4	0
193	Reply to V. Fallet et al.. *Journal of Clinical Oncology*, **2022**, JCO2200782	2.2	0
192	Towards implementation of comprehensive breast cancer risk prediction tools in health care for personalised prevention.. *Preventive Medicine*, **2022**, 107075	4.3	0
191	Personalised Risk Prediction in Hereditary Breast and Ovarian Cancer: A Protocol for a Multi-Centre Randomised Controlled Trial. *Cancers*, **2022**, 14, 2716	6.6	1
190	CanRisk Tool-A Web Interface for the Prediction of Breast and Ovarian Cancer Risk and the Likelihood of Carrying Genetic Pathogenic Variants. *Cancer Epidemiology Biomarkers and Prevention* , **2021**, 30, 469-473	4	14
189	Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. *Journal of Medical Genetics*, **2021**,	5.8	5
188	Risks of breast and ovarian cancer for women harboring pathogenic missense variants in BRCA1 and BRCA2 compared with those harboring protein truncating variants.. *Genetics in Medicine*, **2021**,	8.1	2
187	Performance of Breast Cancer Polygenic Risk Scores in 760 Female CHEK2 Germline Mutation Carriers. *Journal of the National Cancer Institute*, **2021**, 113, 893-899	9.7	4
186	Prospective Evaluation of the Addition of Polygenic Risk Scores to Breast Cancer Risk Models. *JNCI Cancer Spectrum*, **2021**, 5, pkab021	4.6	3
185	Prospective evaluation of a breast-cancer risk model integrating classical risk factors and polygenic risk in 15 cohorts from six countries. *International Journal of Epidemiology*, **2021**,	7.8	6
184	Improving reporting standards for polygenic scores in risk prediction studies. *Nature*, **2021**, 591, 211-219	50.4	70
183	Characterisation of PALB2 tumours through whole-exome and whole-transcriptomic analyses. *Npj Breast Cancer*, **2021**, 7, 46	7.8	1

182	Characterisation of protein-truncating and missense variants in in 15 768 women from Malaysia and Singapore. *Journal of Medical Genetics*, **2021**,	5.8	1
181	Personalized Risk Assessment for Prevention and Early Detection of Breast Cancer: Integration and Implementation (PERSPECTIVE I&I). *Journal of Personalized Medicine*, **2021**, 11,	3.6	13
180	The predictive ability of the 313 variant-based polygenic risk score for contralateral breast cancer risk prediction in women of European ancestry with a heterozygous BRCA1 or BRCA2 pathogenic variant. *Genetics in Medicine*, **2021**, 23, 1726-1737	8.1	2
179	A case-only study to identify genetic modifiers of breast cancer risk for BRCA1/BRCA2 mutation carriers. *Nature Communications*, **2021**, 12, 1078	17.4	4
178	RNF168 regulates R-loop resolution and genomic stability in BRCA1/2-deficient tumors. *Journal of Clinical Investigation*, **2021**, 131,	15.9	11
177	Comparative validation of the BOADICEA and Tyrer-Cuzick breast cancer risk models incorporating classical risk factors and polygenic risk in a population-based prospective cohort of women of European ancestry. *Breast Cancer Research*, **2021**, 23, 22	8.3	12
176	Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women. *New England Journal of Medicine*, **2021**, 384, 428-439	59.2	143
175	Potential of polygenic risk scores for improving population estimates of women© breast cancer genetic risks. *Genetics in Medicine*, **2021**, 23, 2114-2121	8.1	3
174	Oral contraceptive use and ovarian cancer risk for BRCA1/2 mutation carriers: an international cohort study. *American Journal of Obstetrics and Gynecology*, **2021**, 225, 51.e1-51.e17	6.4	9
173	Breast and Prostate Cancer Risks for Male BRCA1 and BRCA2 Pathogenic Variant Carriers Using Polygenic Risk Scores. *Journal of the National Cancer Institute*, **2021**,	9.7	3
172	Altered regulation of BRCA1 exon 11 splicing is associated with breast cancer risk in carriers of BRCA1 pathogenic variants. *Human Mutation*, **2021**, 42, 1488-1502	4.7	0
171	The BARCODE1 Pilot: a feasibility study of using germline single nucleotide polymorphisms to target prostate cancer screening. *BJU International*, **2021**,	5.6	4
170	Should Age-Dependent Absolute Risk Thresholds Be Used for Risk Stratification in Risk-Stratified Breast Cancer Screening?. *Journal of Personalized Medicine*, **2021**, 11,	3.6	3
169	Polygenic risk scores for prediction of breast cancer risk in Asian populations.. *Genetics in Medicine*, **2021**,	8.1	2
168	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. *Nature Genetics*, **2020**, 52, 572-581	36.3	76
167	Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention. *Cancers* , **2020**, 12,	6.6	8
166	Personalized early detection and prevention of breast cancer: ENVISION consensus statement. *Nature Reviews Clinical Oncology*, **2020**, 17, 687-705	19.4	64
165	Prostate Cancer Risk by BRCA2 Genomic Regions. *European Urology*, **2020**, 78, 494-497	10.2	2

164	Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study. *PLoS ONE*, **2020**, 15, e0229999	3.7	19
163	External Validation of Risk Prediction Models Incorporating Common Genetic Variants for Incident Colorectal Cancer Using UK Biobank. *Cancer Prevention Research*, **2020**, 13, 509-520	3.2	4
162	Characterization of the Cancer Spectrum in Men With Germline BRCA1 and BRCA2 Pathogenic Variants: Results From the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *JAMA Oncology*, **2020**, 6, 1218-1230	13.4	25
161	Validation of the BOADICEA model and a 313-variant polygenic risk score for breast cancer risk prediction in a Dutch prospective cohort. *Genetics in Medicine*, **2020**, 22, 1803-1811	8.1	17
160	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. *Journal of the National Cancer Institute*, **2020**, 112, 1242-1250	9.7	51
159	Transcriptome-wide association study of breast cancer risk by estrogen-receptor status. *Genetic Epidemiology*, **2020**, 44, 442-468	2.6	9
158	Letter to the editor: a response to Ming© study on machine learning techniques for personalized breast cancer risk prediction. *Breast Cancer Research*, **2020**, 22, 17	8.3	2
157	Candidate Causal Variants at the 8p12 Breast Cancer Risk Locus Regulate. *Cancers*, **2020**, 12,	6.6	3
156	Alcohol Consumption, Cigarette Smoking, and Risk of Breast Cancer for and Mutation Carriers: Results from The BRCA1 and BRCA2 Cohort Consortium. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 368-378	4	9
155	Risk-reducing salpingo-oophorectomy, natural menopause, and breast cancer risk: an international prospective cohort of BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2020**, 22, 8	8.3	22
154	A New Comprehensive Colorectal Cancer Risk Prediction Model Incorporating Family History, Personal Characteristics, and Environmental Factors. *Cancer Epidemiology Biomarkers and Prevention*, **2020**, 29, 549-557	4	12
153	Non-coding RNAs underlie genetic predisposition to breast cancer. *Genome Biology*, **2020**, 21, 7	18.3	11
152	Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. *European Urology*, **2020**, 77, 24-35	10.2	53
151	Fine-mapping of 150 breast cancer risk regions identifies 191 likely target genes. *Nature Genetics*, **2020**, 52, 56-73	36.3	56
150	Chromatin interactome mapping at 139 independent breast cancer risk signals. *Genome Biology*, **2020**, 21, 8	18.3	12
149	Cancer Risks Associated With Germline Pathogenic Variants: An International Study of 524 Families. *Journal of Clinical Oncology*, **2020**, 38, 674-685	2.2	133
148	Polygenic risk scores and breast and epithelial ovarian cancer risks for carriers of BRCA1 and BRCA2 pathogenic variants. *Genetics in Medicine*, **2020**, 22, 1653-1666	8.1	34
147	European polygenic risk score for prediction of breast cancer shows similar performance in Asian women. *Nature Communications*, **2020**, 11, 3833	17.4	31

146	Immune Cell Associations with Cancer Risk. *IScience*, **2020**, 23, 101296	6.1	2
145	Breast Cancer Polygenic Risk Score and Contralateral Breast Cancer Risk. *American Journal of Human Genetics*, **2020**, 107, 837-848	11	12
144	Association of germline variation with the survival of women with pathogenic variants and breast cancer. *Npj Breast Cancer*, **2020**, 6, 44	7.8	3
143	Meta-analysis of up to 622,409 individuals identifies 40 novel smoking behaviour associated genetic loci. *Molecular Psychiatry*, **2020**, 25, 2392-2409	15.1	45
142	Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study **2020**, 15, e0229999		
141	Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study **2020**, 15, e0229999		
140	Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study **2020**, 15, e0229999		
139	Evaluating clinician acceptability of the prototype CanRisk tool for predicting risk of breast and ovarian cancer: A multi-methods study **2020**, 15, e0229999		
138	Shared heritability and functional enrichment across six solid cancers. *Nature Communications*, **2019** , 10, 431	17.4	45
137	Mendelian randomisation study of height and body mass index as modifiers of ovarian cancer risk in 22,588 BRCA1 and BRCA2 mutation carriers. *British Journal of Cancer*, **2019**, 121, 180-192	8.7	13
136	BRCA1 and BRCA2 pathogenic sequence variants in women of African origin or ancestry. *Human Mutation*, **2019**, 40, 1781-1796	4.7	16
135	Towards controlled terminology for reporting germline cancer susceptibility variants: an ENIGMA report. *Journal of Medical Genetics*, **2019**, 56, 347-357	5.8	19
134	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. *Nature Communications*, **2019**, 10, 1741	17.4	47
133	Risk Prediction Models for Colorectal Cancer Incorporating Common Genetic Variants: A Systematic Review. *Cancer Epidemiology Biomarkers and Prevention*, **2019**, 28, 1580-1593	4	21
132	The :p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. *Npj Breast Cancer*, **2019**, 5, 38	7.8	12
131	Accuracy of Risk Estimates from the iPrevent Breast Cancer Risk Assessment and Management Tool. *JNCI Cancer Spectrum*, **2019**, 3, pkz066	4.6	7
130	Homeobox B13 G84E Mutation and Prostate Cancer Risk. *European Urology*, **2019**, 75, 834-845	10.2	16
129	BOADICEA: a comprehensive breast cancer risk prediction model incorporating genetic and nongenetic risk factors. *Genetics in Medicine*, **2019**, 21, 1708-1718	8.1	192

128	Height and Body Mass Index as Modifiers of Breast Cancer Risk in BRCA1/2 Mutation Carriers: A Mendelian Randomization Study. *Journal of the National Cancer Institute*, **2019**, 111, 350-364	9.7	22
127	CliniciansQuse of breast cancer risk assessment tools according to their perceived importance of breast cancer risk factors: an international survey. *Journal of Community Genetics*, **2019**, 10, 61-71	2.5	5
126	The BRCA2 c.68-7T>A variant is not pathogenic: A model for clinical calibration of spliceogenicity. *Human Mutation*, **2018**, 39, 729-741	4.7	16
125	Current detection rates and time-to-detection of all identifiable carriers in the Greater London population. *Journal of Medical Genetics*, **2018**, 55, 538-545	5.8	30
124	Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations. *Human Mutation*, **2018**, 39, 593-620	4.7	138
123	Tumour risks and genotype-phenotype correlations associated with germline variants in succinate dehydrogenase subunit genes , and. *Journal of Medical Genetics*, **2018**, 55, 384-394	5.8	97
122	Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. *Journal of the National Cancer Institute*, **2018**, 110, 714-725	9.7	92
121	Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women. *American Journal of Obstetrics and Gynecology*, **2018**, 218, 431.e1-431.e12	6.4	23
120	pedigreejs: a web-based graphical pedigree editor. *Bioinformatics*, **2018**, 34, 1069-1071	7.2	5
119	Risks of breast or ovarian cancer in BRCA1 or BRCA2 predictive test negatives: findings from the EMBRACE study. *Genetics in Medicine*, **2018**, 20, 1575-1582	8.1	12
118	Use of the BOADICEA Web Application in clinical practice: appraisals by clinicians from various countries. *Familial Cancer*, **2018**, 17, 31-41	3	6
117	Inherited mutations in and in an unselected multiethnic cohort of Asian patients with breast cancer and healthy controls from Malaysia. *Journal of Medical Genetics*, **2018**, 55, 97-103	5.8	24
116	A Transcriptome-Wide Association Study Among 97,898 Women to Identify Candidate Susceptibility Genes for Epithelial Ovarian Cancer Risk. *Cancer Research*, **2018**, 78, 5419-5430	10.1	32
115	The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing. *JMIR Formative Research*, **2018**, 2, e24	2.5	5
114	The Influence of Number and Timing of Pregnancies on Breast Cancer Risk for Women With or Mutations. *JNCI Cancer Spectrum*, **2018**, 2, pky078	4.6	10
113	Age-specific breast cancer risk by body mass index and familial risk: prospective family study cohort (ProF-SC). *Breast Cancer Research*, **2018**, 20, 132	8.3	24
112	Epidemiology of ATTRV30M neuropathy in Cyprus and the modifier effect of complement C1q on the age of disease onset. *Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis*, **2018**, 25, 220-226	2.7	7
111	BRCA Challenge: BRCA Exchange as a global resource for variants in BRCA1 and BRCA2. *PLoS Genetics*, **2018**, 14, e1007752	6	90

110	Oral Contraceptive Use and Breast Cancer Risk: Retrospective and Prospective Analyses From a BRCA1 and BRCA2 Mutation Carrier Cohort Study. *JNCI Cancer Spectrum*, **2018**, 2, pky023	4.6	13
109	Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. *Journal of Medical Genetics*, **2018**, 55, 546-554	5.8	30
108	Breast cancer risk prediction using a polygenic risk score in the familial setting: a prospective study from the Breast Cancer Family Registry and kConFab. *Genetics in Medicine*, **2017**, 19, 30-35	8.1	31
107	Evaluation of copy-number variants as modifiers of breast and ovarian cancer risk for BRCA1 pathogenic variant carriers. *European Journal of Human Genetics*, **2017**, 25, 432-438	5.3	15
106	Risks of Breast, Ovarian, and Contralateral Breast Cancer for BRCA1 and BRCA2 Mutation Carriers. *JAMA - Journal of the American Medical Association*, **2017**, 317, 2402-2416	27.4	1140
105	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. *Nature Genetics*, **2017**, 49, 680-691	36.3	190
104	Association analysis identifies 65 new breast cancer risk loci. *Nature*, **2017**, 551, 92-94	50.4	643
103	Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. *Nature Genetics*, **2017**, 49, 1767-1778	36.3	186
102	Prediction of Breast and Prostate Cancer Risks in Male BRCA1 and BRCA2 Mutation Carriers Using Polygenic Risk Scores. *Journal of Clinical Oncology*, **2017**, 35, 2240-2250	2.2	101
101	Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry. *American Journal of Obstetrics and Gynecology*, **2017**, 217, 578.e1-578.e12	6.4	39
100	Association of breast cancer risk in BRCA1 and BRCA2 mutation carriers with genetic variants showing differential allelic expression: identification of a modifier of breast cancer risk at locus 11q22.3. *Breast Cancer Research and Treatment*, **2017**, 161, 117-134	4.4	15
99	Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 404-412	4	185
98	The OncoArray Consortium: A Network for Understanding the Genetic Architecture of Common Cancers. *Cancer Epidemiology Biomarkers and Prevention*, **2017**, 26, 126-135	4	183
97	Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers. *Journal of the National Cancer Institute*, **2017**, 109,	9.7	153
96	Risk of breast or ovarian cancer in family members who do not carry the BRCA1 or BRCA2 family mutation: Findings from the EMBRACE study.. *Journal of Clinical Oncology*, **2017**, 35, 1558-1558	2.2	
95	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. *Gynecologic Oncology*, **2016**, 141, 386-401	4.9	15
94	Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers. *Endocrine-Related Cancer*, **2016**, 23, T69-84	5.7	46
93	Inheritance of deleterious mutations at both BRCA1 and BRCA2 in an international sample of 32,295 women. *Breast Cancer Research*, **2016**, 18, 112	8.3	25

92	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. *Nature Communications*, **2016**, 7, 11375	17.4	64
91	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast-ovarian cancer susceptibility locus. *Nature Communications*, **2016**, 7, 12675	17.4	53
90	Combined genetic and splicing analysis of BRCA1 c.[594-2A>C; 641A>G] highlights the relevance of naturally occurring in-frame transcripts for developing disease gene variant classification algorithms. *Human Molecular Genetics*, **2016**, 25, 2256-2268	5.6	55
89	iPrevent : a tailored, web-based, decision support tool for breast cancer risk assessment and management. *Breast Cancer Research and Treatment*, **2016**, 156, 171-82	4.4	25
88	Breast cancer risk variants at 6q25 display different phenotype associations and regulate ESR1, RMND1 and CCDC170. *Nature Genetics*, **2016**, 48, 374-86	36.3	93
87	Refining Breast Cancer Risk Stratification: Additional Genes, Additional Information. *American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting*, **2016**, 35, 44-56	7.1	15
86	Fine-Scale Mapping at 9p22.2 Identifies Candidate Causal Variants That Modify Ovarian Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. *PLoS ONE*, **2016**, 11, e0158801	3.7	7
85	Fine-scale mapping of 8q24 locus identifies multiple independent risk variants for breast cancer. *International Journal of Cancer*, **2016**, 139, 1303-1317	7.5	26
84	Transitioning to routine breast cancer risk assessment and management in primary care: what can we learn from cardiovascular disease?. *Australian Journal of Primary Health*, **2016**, 22, 255-261	1.4	13
83	Specifying the ovarian cancer risk threshold of premenopausal risk-reducing salpingo-oophorectomy for ovarian cancer prevention: a cost-effectiveness analysis. *Journal of Medical Genetics*, **2016**, 53, 591-9	5.8	40
82	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. *Breast Cancer Research*, **2016**, 18, 64	8.3	25
81	Incorporating truncating variants in PALB2, CHEK2, and ATM into the BOADICEA breast cancer risk model. *Genetics in Medicine*, **2016**, 18, 1190-1198	8.1	64
80	The PROFILE Feasibility Study: Targeted Screening of Men With a Family History of Prostate Cancer. *Oncologist*, **2016**, 21, 716-22	5.7	24
79	Male breast cancer in BRCA1 and BRCA2 mutation carriers: pathology data from the Consortium of Investigators of Modifiers of BRCA1/2. *Breast Cancer Research*, **2016**, 18, 15	8.3	58
78	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. *Nature Genetics*, **2015**, 47, 164-71	36.3	177
77	Breast cancer risk in women with PALB2 mutations in different populations. *Lancet Oncology, The*, **2015**, 16, e375-6	21.7	8
76	Risk Analysis of Prostate Cancer in PRACTICAL, a Multinational Consortium, Using 25 Known Prostate Cancer Susceptibility Loci. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 1121-9	4	46
75	Association of type and location of BRCA1 and BRCA2 mutations with risk of breast and ovarian cancer. *JAMA - Journal of the American Medical Association*, **2015**, 313, 1347-61	27.4	286

74	Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair. *Nature Genetics*, **2015**, 47, 1294-1303	36.3	226
73	A risk prediction algorithm for ovarian cancer incorporating BRCA1, BRCA2, common alleles and other familial effects. *Journal of Medical Genetics*, **2015**, 52, 465-75	5.8	43
72	Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. *Journal of the National Cancer Institute*, **2015**, 107,	9.7	239
71	Effect of BRCA Mutations on Metastatic Relapse and Cause-specific Survival After Radical Treatment for Localised Prostate Cancer. *European Urology*, **2015**, 68, 186-93	10.2	192
70	Candidate genetic modifiers for breast and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2015**, 24, 308-16	4	20
69	An original phylogenetic approach identified mitochondrial haplogroup T1a1 as inversely associated with breast cancer risk in BRCA2 mutation carriers. *Breast Cancer Research*, **2015**, 17, 61	8.3	16
68	Assessing associations between the AURKA-HMMR-TPX2-TUBG1 functional module and breast cancer risk in BRCA1/2 mutation carriers. *PLoS ONE*, **2015**, 10, e0120020	3.7	26
67	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. *Human Molecular Genetics*, **2015**, 24, 3595-607	5.6	32
66	Gene-panel sequencing and the prediction of breast-cancer risk. *New England Journal of Medicine*, **2015**, 372, 2243-57	59.2	587
65	Rare coding variants and X-linked loci associated with age at menarche. *Nature Communications*, **2015**, 6, 7756	17.4	23
64	Germline mutation in BRCA1 or BRCA2 and ten-year survival for women diagnosed with epithelial ovarian cancer. *Clinical Cancer Research*, **2015**, 21, 652-7	12.9	107
63	Attenuated familial adenomatous polyposis manifests as autosomal dominant late-onset colorectal cancer. *European Journal of Human Genetics*, **2014**, 22, 1330-3	5.3	15
62	Breast-cancer risk in families with mutations in PALB2. *New England Journal of Medicine*, **2014**, 371, 497-506	59.2	576
61	Assessing and managing breast cancer risk: cliniciansÕ current practice and future needs. *Breast*, **2014**, 23, 644-50	3.6	33
60	Ovarian cancer familial relative risks by tumour subtypes and by known ovarian cancer genetic susceptibility variants. *Journal of Medical Genetics*, **2014**, 51, 108-13	5.8	47
59	DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers. *PLoS Genetics*, **2014**, 10, e1004256	6	33
58	Common non-synonymous SNPs associated with breast cancer susceptibility: findings from the Breast Cancer Association Consortium. *Human Molecular Genetics*, **2014**, 23, 6096-111	5.6	48
57	Refined histopathological predictors of BRCA1 and BRCA2 mutation status: a large-scale analysis of breast cancer characteristics from the BCAC, CIMBA, and ENIGMA consortia. *Breast Cancer Research* , **2014**, 16, 3419	8.3	82

56	Breast and ovarian cancer risks in a large series of clinically ascertained families with a high proportion of BRCA1 and BRCA2 Dutch founder mutations. *Journal of Medical Genetics*, **2014**, 51, 98-107	5.8	62
55	Lymphocyte telomere length is long in BRCA1 and BRCA2 mutation carriers regardless of cancer-affected status. *Cancer Epidemiology Biomarkers and Prevention*, **2014**, 23, 1018-24	4	12
54	Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2014**, 16, 3416	8.3	46
53	The PROFILE feasibility study: Genetic prostate cancer risk stratification for targeted screening.. *Journal of Clinical Oncology*, **2014**, 32, 22-22	2.2	
52	Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. *Journal of Clinical Oncology*, **2013**, 31, 1748-57	2.2	440
51	Cancer risks for BRCA1 and BRCA2 mutation carriers: results from prospective analysis of EMBRACE. *Journal of the National Cancer Institute*, **2013**, 105, 812-22	9.7	616
50	Tamoxifen and risk of contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. *Journal of Clinical Oncology*, **2013**, 31, 3091-9	2.2	118
49	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. *Nature Genetics*, **2013**, 45, 371-84, 384e1-2	36.3	422
48	Evaluating the performance of the breast cancer genetic risk models BOADICEA, IBIS, BRCAPRO and Claus for predicting BRCA1/2 mutation carrier probabilities: a study based on 7352 families from the German Hereditary Breast and Ovarian Cancer Consortium. *Journal of Medical Genetics*, **2013**, 50, 360-7	5.8	76
47	Identification of a BRCA2-specific modifier locus at 6p24 related to breast cancer risk. *PLoS Genetics*, **2013**, 9, e1003173	6	90
46	Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk. *PLoS Genetics*, **2013**, 9, e1003212	6	209
45	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. *Nature Communications*, **2013**, 4, 1627	17.4	85
44	Development of a tailored, computerized, breast cancer risk assessment and decision support tool: What do clinicians want?. *Journal of Clinical Oncology*, **2013**, 31, e20660-e20660	2.2	1
43	Assessing breast cancer risk in primary care: What can we learn from cardiovascular disease?. *Journal of Clinical Oncology*, **2013**, 31, 17-17	2.2	1
42	Effect of germ-line BRCA mutations in biochemical relapse and survival after treatment for localized prostate cancer.. *Journal of Clinical Oncology*, **2013**, 31, 29-29	2.2	1
41	Profile study: Genetic prostate cancer risk stratification for targeted screening.. *Journal of Clinical Oncology*, **2013**, 31, 5054-5054	2.2	
40	Assessing breast cancer risk in primary care: What can we learn from cardiovascular disease?. *Journal of Clinical Oncology*, **2013**, 31, 1559-1559	2.2	
39	Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers. *Breast Cancer Research*, **2012**, 14, R33	8.3	70

38	Ovarian cancer susceptibility alleles and risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. *Human Mutation*, **2012**, 33, 690-702	4.7	31
37	Clinical software development for the Web: lessons learned from the BOADICEA project. *BMC Medical Informatics and Decision Making*, **2012**, 12, 30	3.6	8
36	Evaluation of association methods for analysing modifiers of disease risk in carriers of high-risk mutations. *Genetic Epidemiology*, **2012**, 36, 274-91	2.6	33
35	Germline RAD51C mutations confer susceptibility to ovarian cancer. *Nature Genetics*, **2012**, 44, 475-6; author reply 476	36.3	190
34	Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 645-57	4	44
33	Pathology of breast and ovarian cancers among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA). *Cancer Epidemiology Biomarkers and Prevention*, **2012**, 21, 134-47	4	411
32	Comparison of 6q25 breast cancer hits from Asian and European Genome Wide Association Studies in the Breast Cancer Association Consortium (BCAC). *PLoS ONE*, **2012**, 7, e42380	3.7	49
31	BRCA carrier status as an independent prognostic factor associated with earlier biochemical relapse in local prostate cancer.. *Journal of Clinical Oncology*, **2012**, 30, 1545-1545	2.2	
30	Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2011**, 20, 3304-21	5.6	62
29	Genetic variation at 9p22.2 and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers. *Journal of the National Cancer Institute*, **2011**, 103, 105-16	9.7	37
28	Germline mutations in RAD51D confer susceptibility to ovarian cancer. *Nature Genetics*, **2011**, 43, 879-882	36.3	379
27	A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast cancer in the general population. *Nature Genetics*, **2010**, 42, 885-92	36.3	276
26	Common breast cancer susceptibility alleles and the risk of breast cancer for BRCA1 and BRCA2 mutation carriers: implications for risk prediction. *Cancer Research*, **2010**, 70, 9742-54	10.1	147
25	Common genetic variants and cancer risk in Mendelian cancer syndromes. *Current Opinion in Genetics and Development*, **2010**, 20, 299-307	4.9	23
24	Incorporating tumour pathology information into breast cancer risk prediction algorithms. *Breast Cancer Research*, **2010**, 12, R28	8.3	54
23	Familial relative risks for breast cancer by pathological subtype: a population-based cohort study. *Breast Cancer Research*, **2010**, 12, R10	8.3	27
22	Common variants in LSP1, 2q35 and 8q24 and breast cancer risk for BRCA1 and BRCA2 mutation carriers. *Human Molecular Genetics*, **2009**, 18, 4442-56	5.6	91
21	Reproductive and hormonal factors, and ovarian cancer risk for BRCA1 and BRCA2 mutation carriers: results from the International BRCA1/2 Carrier Cohort Study. *Cancer Epidemiology Biomarkers and Prevention*, **2009**, 18, 601-10	4	110

20	The average cumulative risks of breast and ovarian cancer for carriers of mutations in BRCA1 and BRCA2 attending genetic counseling units in Spain. *Clinical Cancer Research*, **2008**, 14, 2861-9	12.9	77
19	Common breast cancer-predisposition alleles are associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers. *American Journal of Human Genetics*, **2008**, 82, 937-48	11	218
18	Age at menarche and menopause and breast cancer risk in the International BRCA1/2 Carrier Cohort Study. *Cancer Epidemiology Biomarkers and Prevention*, **2007**, 16, 740-6	4	56
17	Oral contraceptives and breast cancer risk in the international BRCA1/2 carrier cohort study: a report from EMBRACE, GENEPSO, GEO-HEBON, and the IBCCS Collaborating Group. *Journal of Clinical Oncology*, **2007**, 25, 3831-6	2.2	116
16	RAD51 135G-->C modifies breast cancer risk among BRCA2 mutation carriers: results from a combined analysis of 19 studies. *American Journal of Human Genetics*, **2007**, 81, 1186-200	11	204
15	An international initiative to identify genetic modifiers of cancer risk in BRCA1 and BRCA2 mutation carriers: the Consortium of Investigators of Modifiers of BRCA1 and BRCA2 (CIMBA). *Breast Cancer Research*, **2007**, 9, 104	8.3	121
14	Mammographic density and breast cancer risk in BRCA1 and BRCA2 mutation carriers. *Cancer Research*, **2006**, 66, 1866-72	10.1	111
13	Pregnancies, breast-feeding, and breast cancer risk in the International BRCA1/2 Carrier Cohort Study (IBCCS). *Journal of the National Cancer Institute*, **2006**, 98, 535-44	9.7	161
12	Risk prediction models for familial breast cancer. *Future Oncology*, **2006**, 2, 257-74	3.6	72
11	BRCA1 and BRCA2 mutation predictions using the BOADICEA and BRCAPRO models and penetrance estimation in high-risk French-Canadian families. *Breast Cancer Research*, **2006**, 8, R3	8.3	64
10	Parity and breast cancer risk among BRCA1 and BRCA2 mutation carriers. *Breast Cancer Research*, **2006**, 8, R72	8.3	54
9	A weighted cohort approach for analysing factors modifying disease risks in carriers of high-risk susceptibility genes. *Genetic Epidemiology*, **2005**, 29, 1-11	2.6	127
8	Polygenic inheritance of breast cancer: Implications for design of association studies. *Genetic Epidemiology*, **2003**, 25, 190-202	2.6	197
7	Polygenic susceptibility to breast cancer and implications for prevention. *Nature Genetics*, **2002**, 31, 33-6	36.3	780
6	Evidence for further breast cancer susceptibility genes in addition to BRCA1 and BRCA2 in a population-based study. *Genetic Epidemiology*, **2001**, 21, 1-18	2.6	234
5	Risk models for familial ovarian and breast cancer. *Genetic Epidemiology*, **2000**, 18, 173-90	2.6	128
4	Risk models for familial ovarian and breast cancer **2000**, 18, 173		1
3	Enhancing the BOADICEA cancer risk prediction model to incorporate new data on RAD51C, RAD51D, BARD1, updates to tumour pathology and cancer incidences		1

2	A Comprehensive Epithelial Tubo-Ovarian Cancer Risk Prediction Model Incorporating Genetic and Epidemiological Risk Factors	2
1	Segregation analysis of 17,425 population-based breast cancer families: evidence for genetic susceptibility and risk prediction	1